John Pedersen

Mr. Pedersen joined DYSIS Medical as Chairman of the Board in December 2019.  Prior to joining the Board of Directors, Mr. Pedersen was CEO at Augmenix, Inc., which in was acquired by Boston Scientific Corp. in late 2018.  Previous to Augmenix, he was a Senior Healthcare Advisor for two Healthcare Private Equity Funds – The Gores Group and The Pritzker Group. Prior to this, Mr. Pedersen was President of the Urology and Women’s Health Division at Boston Scientific. During his 15 years at Boston Scientific, he also served as President of the Peripheral Interventions and the Neurovascular Divisions. Prior to Boston Scientific, he was a Senior Engagement Manager at McKinsey & Co.  Mr. Pedersen earned an MBA from The Harvard Graduate School of Business Administration and an AB degree from Princeton University.